Sarepta Therapeutics, Inc. (SRPT)
17.10
-0.69
(-3.88%)
USD |
NASDAQ |
Oct 16, 16:00
17.10
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Cash from Investing (Quarterly) : -93.37M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -93.37M |
| March 31, 2026 | -134.39M |
| December 31, 2025 | 96.21M |
| September 30, 2025 | 232.40M |
| June 30, 2025 | 32.21M |
| March 31, 2025 | -291.18M |
| December 31, 2024 | 764.12M |
| September 30, 2024 | -128.82M |
| June 30, 2024 | -98.53M |
| March 31, 2024 | 218.80M |
| December 31, 2023 | -64.36M |
| September 30, 2023 | -210.57M |
| June 30, 2023 | 96.63M |
| March 31, 2023 | 12.49M |
| December 31, 2022 | 9.796M |
| September 30, 2022 | 19.12M |
| June 30, 2022 | -289.99M |
| March 31, 2022 | -785.81M |
| December 31, 2021 | -2.577M |
| September 30, 2021 | 20.26M |
| June 30, 2021 | 321.06M |
| March 31, 2021 | 156.67M |
| December 31, 2020 | -123.89M |
| September 30, 2020 | 54.08M |
| June 30, 2020 | -34.22M |
| Date | Value |
|---|---|
| March 31, 2020 | -17.68M |
| December 31, 2019 | 17.08M |
| September 30, 2019 | -17.96M |
| June 30, 2019 | 152.37M |
| March 31, 2019 | 135.23M |
| December 31, 2018 | -237.74M |
| September 30, 2018 | -63.40M |
| June 30, 2018 | -55.09M |
| March 31, 2018 | -14.26M |
| December 31, 2017 | -493.70M |
| September 30, 2017 | 124.95M |
| June 30, 2017 | -20.05M |
| March 31, 2017 | 209.98M |
| December 31, 2016 | -198.77M |
| September 30, 2016 | 10.22M |
| June 30, 2016 | 78.94M |
| March 31, 2016 | 19.42M |
| December 31, 2015 | -69.82M |
| September 30, 2015 | 31.02M |
| June 30, 2015 | 3.383M |
| March 31, 2015 | 43.83M |
| December 31, 2014 | 46.68M |
| September 30, 2014 | -20.54M |
| June 30, 2014 | -2.877M |
| March 31, 2014 | -182.29M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Moderna, Inc. | 329.00M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Beam Therapeutics, Inc. | -9.875M |
| Rocket Pharmaceuticals, Inc. | 214.36M |
| Intellia Therapeutics, Inc. | -141.57M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 197.07M |
| Free Cash Flow | 58.34M |
| Free Cash Flow Per Share (Quarterly) | 1.864 |
| Free Cash Flow to Equity (Quarterly) | 187.33M |
| Free Cash Flow to Firm (Quarterly) | 256.65M |
| Free Cash Flow Yield | 3.16% |